These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 28455750)
1. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Dombrowski S; Kostev K; Jacob L Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750 [TBL] [Abstract][Full Text] [Related]
2. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565 [TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504 [TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study. Hou WH; Chang KC; Li CY; Ou HT Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544 [TBL] [Abstract][Full Text] [Related]
5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Ou HT; Chang KC; Li CY; Wu JS Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742 [TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study. Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540 [TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitor treatment could decrease Chen HH; Chen CC; Ho CW; Hsieh MC; Hsu SP; Lin CL; Kao CH Postgrad Med; 2020 Nov; 132(8):714-719. PubMed ID: 32633173 [TBL] [Abstract][Full Text] [Related]
8. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127 [TBL] [Abstract][Full Text] [Related]
9. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population. Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. Ha KH; Kim B; Choi H; Kim DJ; Kim HC Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719 [TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study. Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989 [TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study. Hou WH; Chang KC; Li CY; Ou HT Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847 [TBL] [Abstract][Full Text] [Related]
13. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study. Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172 [TBL] [Abstract][Full Text] [Related]
14. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. Rathmann W; Kostev K J Diabetes Complications; 2017 Apr; 31(4):687-692. PubMed ID: 28169131 [TBL] [Abstract][Full Text] [Related]
15. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort. Cho YY; Cho SI Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797 [TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease. Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741 [TBL] [Abstract][Full Text] [Related]
17. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Rathmann W; Kostev K; Gruenberger JB; Dworak M; Bader G; Giani G Diabetes Obes Metab; 2013 Jan; 15(1):55-61. PubMed ID: 22862879 [TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Seong JM; Yee J; Gwak HS Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554 [TBL] [Abstract][Full Text] [Related]
19. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan. Shikamura M; Takayama A; Takeuchi M; Kawakami K Diabetes Obes Metab; 2024 Aug; 26(8):3099-3109. PubMed ID: 38708591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]